Precipio is a healthcare biotechnology company focused on cancer diagnostics. Co. develops and sells diagnostic products, reagents and services. The first panel developed using HemeScreen technology was Co.'s Myeloproliferative Neoplasms panel. Co. has since added Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Cytopenia, and BCR-ABL panels, evolving HemeScreen into a suite of genetic diagnostic panels. Co.'s IV-Cell is a proprietary cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a media that enables simultaneous culturing of four hematopoietic cell lineages. The PRPO average annual return since 2017 is shown above.
The Average Annual Return on the PRPO average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PRPO average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRPO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free PRPO Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
